By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

The UK's National Screening Committee has recommended that only a very small group of men at high risk of prostate cancer ...

Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

A whole-food plant-based diet can significantly increase weight loss for men with prostate cancer and overweight or obesity ...

Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...